Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
TEL AVIV, Israel, Feb. 02, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2015 before the market open, and will host a corporate update conference call and webcast on Wednesday, February 17 at 8:30 am Eastern Time.
| Conference Call & Webcast | |
| Wednesday, February 17, 2016 @ 8:30am Eastern Time | |
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Passcode: | 34475008 |
| Webcast: | http://www.alcobra-pharma.com/events.cfm |
| Replays available through March 2, 2016 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 34475008 |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 [email protected] Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 [email protected]
